Hot Topics

Biomarin Stock Hits New 52-Week High (BMRN)

Biomarin Pharmaceutical (Nasdaq:BMRN) hit a new 52-week high Monday as it is currently trading at $63.02, above its previous 52-week high of $62.96 with 107,553 shares traded as of 9:40 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Biomarin Pharmaceutical (Nasdaq: BMRN) hit a new 52-week high Monday as it is currently trading at $63.02, above its previous 52-week high of $62.96 with 107,553 shares traded as of 9:40 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Biomarin has a market cap of $7.85 billion and is part of the health care sector and drugs industry. Shares are up 26.5% year to date as of the close of trading on Thursday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Biomarin as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Biomarin Ratings Report.